Skip to content

Debt Maturity - 2024 at other companies

Morgan Stanley logo
Morgan StanleyMS
$115.47B+14.7%
U.S. Bancorp logo
U.S. BancorpUSB
$11.65B-13.6%
Globalstar logo
GlobalstarGSAT
$1.56M
Merck & Co. logo
Merck & Co.MRK
$1.7B+54.5%
Southern Company logo
Southern CompanySO
$45M
Morgan Stanley logo
Morgan StanleyMS
$20.02B-9.8%

Other financials

Income statement

See full
Revenue$311.3M+127%
Gross profit$43.5M
Operating income-$92.7M-16.9%
Net income-$94.4M-28.9%
EPS (diluted)-$3.25-24.5%

Balance sheet

See full
Cash & equivalents$232.2M+23.1%
Total debt$377.3M+187%
Total equity$543.5M-23.5%
Total assets$1.2B+23.1%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$3.8M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.66B+64.2%
Enterprise value$11.81B+67.5%
P/S10.3×-12.1×

Profitability

See full
Gross margin96.5%
Operating margin-27.7%-12.2pp
Net margin-27.3%-12.0pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-49.3%-0.8pp
Debt / equity0.7×+0.5×
Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s debt maturity - 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s debt maturity - 2024?
Madrigal Pharmaceuticals, Inc. (MDGL) reported debt maturity - 2024 of $22.59M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s debt maturity - 2024 changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s debt maturity - 2024 increased by 158.4% year-over-year, from $8.74M to $22.59M.